Novo Nordisk Price Cut 2027: Wegovy, Ozempic Dropping to $675/mo

Novo Nordisk Is Cutting Prices — Here's What It Means

In February 2026, Novo Nordisk announced that the list prices of Wegovy, Ozempic, and Rybelsus will all drop to $675 per month at any dose level, effective January 1, 2027. That's a 35–50% reduction from current list prices of $969–$1,349 per month.

This is the most significant price reduction in the GLP-1 market since these drugs launched. But what does it actually mean for what you pay? The answer depends on your insurance status.

Who Benefits Most From This Price Cut

Insured Patients With Percentage-Based Copays

If your insurance copay is calculated as a percentage of the drug's list price (common with many commercial plans), the price cut directly reduces what you owe. A patient paying 20% coinsurance on Wegovy would see their monthly cost drop from ~$270 to ~$135.

Patients in the Medicare Part D "Donut Hole"

Medicare Part D beneficiaries who hit the coverage gap pay a percentage of the drug's list price. A lower list price means a lower donut hole cost. Combined with the $50/month bridge program starting July 2026, Medicare patients are seeing historic cost relief.

Patients With High-Deductible Plans

If you haven't met your deductible, you're paying list price (or close to it). A $675/month Wegovy is substantially more manageable than $1,349/month Wegovy while you work through your deductible.

Who Won't Notice a Difference

Patients Using Self-Pay Programs

If you're already on the NovoCare self-pay programs ($149/mo for the pill, $199/mo injection intro, $349/mo maintenance), the list price reduction doesn't change your cost. You're already paying well below list price.

Patients Using Compounded Semaglutide

Compounded semaglutide at $146–$299/month is already cheaper than the new $675 list price. However, the price cut may weaken the cost argument for compounding over time, particularly if insurance coverage expands at the lower price point.

Uninsured Cash-Pay Patients

The list price reduction matters most within the insurance system. If you're paying cash at a retail pharmacy without any manufacturer program, $675/month is better than $1,349 — but NovoCare's $149–$349 self-pay programs are still cheaper.

The Bigger Picture: A GLP-1 Price War

Novo Nordisk's price cut didn't happen in a vacuum. Eli Lilly had already lowered Zepbound pricing with their vial program ($299/month) and KwikPen self-pay ($449/month). The Wegovy pill at $149/month was another competitive move. Now the list price cut completes the picture.

This is a genuine price war between the two largest GLP-1 manufacturers, driven by several forces: political pressure on drug pricing, expanding Medicare coverage, the threat of compounding, and competition for market share.

For patients, this is unambiguously good news. Prices are falling across every access pathway simultaneously.

What You Should Do Now

If you're currently on a GLP-1: Check whether your insurance copay is percentage-based. If so, your costs should drop automatically starting January 2027. Contact your insurer to confirm.

If you're considering starting: Don't wait until January 2027 for the list price cut. The self-pay programs available today ($149–$349/month) are already cheaper than the new list price will be. Start now and benefit from the list price reduction later if it improves your insurance terms.

If you're on compounded semaglutide: This price cut doesn't change your situation immediately, but monitor the market. As brand-name prices fall, the gap between FDA-approved and compounded options narrows, and the regulatory pressure on compounding intensifies.

The Bottom Line

Novo Nordisk's price cut to $675/month is a landmark moment for GLP-1 affordability — but the real story is the combination of forces driving costs down: manufacturer competition, self-pay programs, Medicare coverage, and compounded alternatives.

The best price available today remains lower than $675. Check our pricing table for every current option.